Lupin receives USFDA approval for Triamcinolone Acetonide Cream

04 Feb 2017 Evaluate

Lupin has received final approval for its Triamcinolone Acetonide Cream USP, 0.025%, 0.1% and 0.5% from the United States Food and Drug Administration (USFDA) to market a generic equivalent of Mylan Pharmaceuticals Inc.’s Triamcinolone Acetonide Cream, 0.025% and 0.1%. Lupin shall commence promoting the product shortly. Triamcinolone Acetonide Cream USP, 0.025%, 0.1% and 0.5% had US sales of $55.7 million, as per IMS MAT Sep 2016.

Lupin’s Triamcinolone Acetonide Cream USP, 0.025%, 0.1% and 0.5% is an AT rated generic equivalent of Mylan Pharmaceuticals, Inc.’s (formerly held by Delcor Asset Corporation) Triamcinolone Acetonide Cream, 0.025% and 0.1%. Triamcinolone Acetonide Cream USP, 0.025%, 0.1% and 0.5% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.


Lupin Share Price

2055.05 3.00 (0.15%)
10-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1786.25
Dr. Reddys Lab 1251.10
Cipla 1489.15
Zydus Lifesciences 923.70
Lupin 2055.05
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×